Send us a text

Episode 19 Allergic Rhinitis

Shoot me any comments or questions @Rotation2ptoh  on X

Intro: Rock Christmas/ Christmas Music by tramp963

Outro: Tokyo Café by TVARI

Courtesy of Pixabay for non-commercial educational use

Produced by: Todd Fredricks DO MSS

Edited by: Todd Fredricks DO MSS

Questions and Answers from Episode 18  

Question 1

A 35-year-old male patient presents with newly diagnosed pulmonary tuberculosis (TB) confirmed to be drug-susceptible (DS-TB). The patient has non-cavitary disease and a low bacillary burden. Based on recent clinical trial evidence and World Health Organization (WHO) guidelines, which of the following treatment regimens is most appropriate for this patient?

 B. 4 months of rifapentine, moxifloxacin, isoniazid, and pyrazinamide
 
 Question 2

A 42-year-old female patient is diagnosed with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) without fluoroquinolone resistance. The patient has no contraindications to new TB drugs. Based on the most recent WHO recommendations and clinical trial data, which regimen is the preferred treatment option for this patient?

 B. 6 months of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)

Question 3

A 50-year-old male patient with pre-extensively drug-resistant tuberculosis (pre-XDR TB, defined as MDR/RR-TB with fluoroquinolone resistance) is being considered for a new treatment regimen. The patient has no baseline resistance to bedaquiline or linezolid. Which of the following regimens, supported by recent clinical trial evidence, is most appropriate, and what is a key consideration for its use?

A. 6–9 months of bedaquiline, linezolid, clofazimine, and delamanid; monitor for linezolid-associated toxicity

Paper for next week

Yerem Yeghiazarians, Hani Jneid, Jeremy R. Tietjens, Susan Redline, Devin L. Brown, Nabil El-Sherif, Reena Mehra, Biykem Bozkurt, Chiadi Ericson Ndumele, Virend K. Somers, Obstructive Sleep Apnea and Cardiovascular Disease A Scientific Statement From the American Heart Association, July 20, 2021 Circulation. 2021;144:

Rotations  2.0 is copyrighted. But you can use any content from the podcast for non-commercial purposes under Creative Commons….BUT, BUT, BUT, you must cite Rotations 2.0 and Todd Fredricks DO MSS as the source of the material AND AND AND you cannot alter or edit the content in any manner without expressed permission of Todd Fredricks DO MSS.

Rotations 2.0 is made possible by the generous understanding and accommodation of my beloved institution, Ohio University. The comments and ideas expressed on Rotations 2.0 are that of the content creators alone and may not reflect official policy or the opinion of the Ohio University, the State of Ohio, or the US Government or any other state, person or governmental agency.

Listeners interested in specifics from the paper authors should contact them directly through their respective institutions.

Any therapeutic ideas discussed should not be taken as any kind of medical advice or recommendations by the content creators and the content creators are not offering medical advice but discussing topics from an academic perspective. Listeners seeking advice about any medical care or decision-making should consult their own physician or medical provider and the content creators of Rotations 2.0 assume no liability for any listener's care or decision-making stemming from the topics discussed on Rotations 2.0.